Market Place
Reply
1. Carboplatin 150 mg N1 9000 Units/year
2. Calcium folinate 100 mg/10 ml N1 24000 Units/year
3. Docetaxel 10 mg/ml 2 ml N1 6300 Units/year
4. Docetaxel 10 mg/ml 8 ml N1 1500 Units/year
5. Doxorubicin 50 mg/25 ml N1 2 mg/ml 25 ml N1 4000 Units/year
6. Doxorubicin 10 mg/5 ml N1 2 mg/ml 5 ml N1 5000 Units/year
7. Etoposide 100 mg/5 ml N1 20 mg/ml amp. 5ml N1 13000 Units/year
8. Fluorouracil 50 mg/ ml 5 ml (250 mg) 10000 Units/year
9. Fluorouracil 50 mg/ ml 10 ml (500 mg) 20000 Units/year
10. Paclitaxel 6 mg/ ml 30 mg N1 14500 Units/year
Interested companies/partners are requested to share their contact details to schedule a meet at CPhI Europe.
Comments :
prateek@vamahw.com
+917045548849
rakesh.chaurasia@dexa-medica.com
we would like to see this business potential
licensing@aqvida.com
We can provide most of the entire portfolio - MRP possible from Germany.
Please connect with us under licensing@aqvida.com [Mr. Jurgen Lehmberg, Commercial Director] - more under http://www.aqvida.com
We are TEDEC-MEIJI in Spain.
We can offer Doxorubicine vials
amdoshi@umedicalabs.com
Dear Sir,
Umedica Laboratories is a vertically intergrated, generics manufacturing company with operations in over 50 countries worlwide. We are USFDA AND EDQM approved and would be interested to work with you in Lithuania. Please visit our website (http://www.umedicalabs.com) and also visit us at stall no 110B12 at CPHI to discuss further. - Amoli Doshi
sumit@saappharma.com
Dear Sir,
We can deliver the following products ;- Sr.
No. Product
(Innovator Brand Name) Indication European Dossier Status
1 Temozolomide (Temodal) Glioblastoma multiforme Available*
2 Capecitabine (Xeloda) Chemotherapy drug for multiple cancers Available*
3 Pemetrexed (Alimta) NSCLC & plural mesothelioma Aug 2017
4 Lenalidomide (Revlimid) ** Multiple myeloma and Myelodysplastic Syndrome Available
5 Bortezomib (Velcade) Relapsed Mutiple Myeloma & Mantle Cell Lymphoma Aug 2017
6 Erlotinib (Tarceva) NSCLC & Pancreatic cancer Aug 2017
7 Imatinib (Gleevec) CML (Philadelphia Chromosome positive) Q2 2018
8 Sorafenib (Nexavar) Advanced renal cell carcinoma, advanced hepatocellular carcinoma and advanced thyroid carcinoma Q2 2018
9 Sunitinib (Sutent) Renal cell carcinoma and GIST (Imatinib resistant) Q3 2018
10 Decitabine (Dacogen) AML & Myelodysplastic Syndrome Q3 2018
* Marketing Approval received in UK and Germany
** Already licensed for territories in geographical Europe
pl contact us ;- sumit@saappharma.com
hemil@snehamedicare.com
we can offer you full range of oncology and products which you require and we have WHO-COPP ready please free to contact on hemil@snehamedicare.com
hemant.verma@emcure.co.in
please contact Hemant.verma@emcure.co.in
we have ECTD dossiers for all products
We have a list of potential products. Please contact.
Dehpours@cinnagen.com
We can offer Docetaxel and Paclitaxel.
Please contact us.
kumar.p@accordlifespec.com
Accord life spec is engaged in Development and Manufacturing of Anti cancer finished dosage forms and looking for a strategic partner. please reach me on 8248256894
rnd@swiss.in
Fluorouracil topical solution 5%w/w
export@healthpharma.in
Dear Sir,
Good afternoon.
We can support you for asked products. We request you to send your requirements through email for ease of information.
Awaiting your response.
